Patients with pulmonary arterial hypertension and cardiovascular comorbidities may benefit from the use of inhaled or oral ...
The global Pulmonary Arterial Hypertension (PAH) industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also ...
Flow Medical is developing a thrombolysis catheter that delivers TPA through hollow nitinol tubes to treat pulmonary embolism ...
A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...
Charles Schwab Investment Management Inc. lowered its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free ...
Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less ...
The details of David Murphey’s cause of death have been revealed. The “90 Day’ fiancé” star passed away on Dec. 11 at 66 from ...
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...
Chicago-based Flow Medical is developing a new thrombolysis system for treating acute pulmonary embolism (PE).
They highlighted the underrepresentation of minority groups in pulmonary arterial hypertension (PAH) trials, along with the ...
MannKind Corporation is focused on inhaled therapies for endocrine and orphan lung diseases. Check out my recommendation for ...
1. Merck’s Winrevair (sotatercept) for PAH Winrevair was greenlit March 26 for treating adults with pulmonary arterial hypertension (PAH), based on compelling results from the Phase 3 STELLAR trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback